454 results on '"Dore A"'
Search Results
2. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
3. National trends in retreatment of HCV due to reinfection or treatment failure in Australia
4. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia
5. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
6. WED-422 Screening for viral hepatitis in the emergency department-the methodology to automate a feasible, acceptable and effective solution
7. WED-470 Screening emergency admissions at risk of chronic hepatitis 3 extension (SEARCH 3X)-universal is better than risk-based screening for viral hepatitis
8. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial
9. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia
10. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia
11. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat
12. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study
13. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
14. Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development
15. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
16. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome
17. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)
18. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study
19. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
20. Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada
21. FibroGENE: A gene-based model for staging liver fibrosis
22. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
23. Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake
24. Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270)
25. Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment
26. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection
27. Case definitions for acute hepatitis C virus infection: A systematic review
28. Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis
29. Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets
30. Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study
31. Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study
32. Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study
33. National trends in retreatment of HCV due to reinfection or treatment failure in Australia
34. Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270)
35. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
36. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
37. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006
38. Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study
39. Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis
40. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing
41. Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia
42. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening
43. Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study
44. Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets
45. Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study
46. Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study
47. FRI-169 - Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake
48. Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study
49. Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR
50. Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.